The estimated Net Worth of Giuseppe Ciaramella is at least $13.2 Milión dollars as of 1 April 2024. Giuseppe Ciaramella owns over 4,534 units of Beam Therapeutics stock worth over $4,091,138 and over the last 5 years he sold BEAM stock worth over $7,561,378. In addition, he makes $1,588,450 as President a Chief Scientific Officer at Beam Therapeutics.
Giuseppe has made over 16 trades of the Beam Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 4,534 units of BEAM stock worth $145,632 on 1 April 2024.
The largest trade he's ever made was selling 156,530 units of Beam Therapeutics stock on 21 July 2023 worth over $5,018,352. On average, Giuseppe trades about 28,506 units every 61 days since 2020. As of 1 April 2024 he still owns at least 169,616 units of Beam Therapeutics stock.
You can see the complete history of Giuseppe Ciaramella stock trades at the bottom of the page.
Dr. Giuseppe Ciaramella Ph.D. serves as President, Chief Scientific Officer of the Company. Dr. Ciaramella has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans, several of which are progressing through clinical studies. From 2011 until 2014, Dr. Ciaramella served as Executive Director at Astrazeneca, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the U.K. where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London.
As the President a Chief Scientific Officer of Beam Therapeutics, the total compensation of Giuseppe Ciaramella at Beam Therapeutics is $1,588,450. There are 2 executives at Beam Therapeutics getting paid more, with Terry-Ann Burrell having the highest compensation of $4,302,720.
Giuseppe Ciaramella is 51, he's been the President a Chief Scientific Officer of Beam Therapeutics since 2020. There are 7 older and 9 younger executives at Beam Therapeutics. The oldest executive at Beam Therapeutics Inc. is Mark Fishman, 68, who is the Independent Director.
Giuseppe's mailing address filed with the SEC is C/O BEAM THERAPEUTICS INC.,, 238 MAIN STREET, CAMBRIDGE, MA, 02142.
Over the last 5 years, insiders at Beam Therapeutics have traded over $63,012,019 worth of Beam Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Llc Fmr a Kristina Burow. On average, Beam Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $1,019,987. The most recent stock trade was executed by Amy Simon on 1 July 2024, trading 1,250 units of BEAM stock currently worth $29,100.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeutics executives and other stock owners filed with the SEC include: